Edition:
United Kingdom

Bavarian Nordic A/S (BAVA.CO)

BAVA.CO on Copenhagen Stock Exchange

214.00DKK
12:25pm GMT
Change (% chg)

kr.-7.50 (-3.39%)
Prev Close
kr.221.50
Open
kr.221.50
Day's High
kr.222.00
Day's Low
kr.212.50
Volume
200,113
Avg. Vol
311,026
52-wk High
kr.444.00
52-wk Low
kr.183.00

Latest Key Developments (Source: Significant Developments)

‍Bavarian Nordic says BARDA exercised option under the contract for freeze-dried Imvamune
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Bavarian Nordic A/S ::‍BAVARIAN NORDIC ANNOUNCES EXERCISE OF CLINICAL OPTION BY US GOVERNMENT UNDER CONTRACT FOR FREEZE-DRIED IMVAMUNE SMALLPOX VACCINE​.BAVARIAN NORDIC A/S SAYS ‍CONTRACT OPTION IS EXPECTED TO BE REVENUE RECOGNIZED BETWEEN 2018 AND 2022​.BAVARIAN NORDIC- OPTION, WHICH REPRESENTS ABOUT $37 MILLION OF TOTAL CONTRACT OF UP TO $539 MILLION, WILL COVER DEVELOPMENT COSTS ASSOCIATED WITH PHASE 3 STUDY​.ANNOUNCEMENT DOES NOT AFFECT COMPANY'S EXPECTATIONS FOR FINANCIAL RESULTS FOR 2017​.  Full Article

Bavarian Nordic Q3 EBIT at DKK 432 million
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - BAVARIAN NORDIC A/S ::‍OUTLOOK FOR 2017 MAINTAINED​.Q3 EBIT DKK 432.0 ‍​ MILLION VERSUS LOSS DKK 124.8 MILLION YEAR AGO.Q3 REVENUE DKK 734.3‍​ MILLION VERSUS DKK 452.3 MILLION YEAR AGO.  Full Article

Bavarian Nordic wins big smallpox vaccine order for U.S. government
Thursday, 28 Sep 2017 

Sept 28 (Reuters) - BAVARIAN NORDIC A/S :SECURES CONTRACT AWARD FOR SUPPLY OF FREEZE-DRIED IMVAMUNE SMALLPOX VACCINE TO THE U.S. GOVERNMENT.INITIAL BASE AWARD SECURES ADDITIONAL IMVAMUNE BULK CONTRACT OF USD 100 MILLION.CONTRACT INCLUDES INITIAL OPTIONS VALUED AT USD 439 MILLION.POTENTIAL VALUE OF INITIAL BASE AND OPTIONAL AWARDS IS IN EXCESS OF $539 MILLION.BAVARIAN NORDIC-AWARD OF CONTRACT FROM BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY FOR PROCUREMENT OF FREEZE-DRIED IMVAMUNE SMALLPOX VACCINE.  Full Article

Bavarian Nordic launches share buy-back program to hedge incentive scheme obligations
Thursday, 18 May 2017 

May 18 (Reuters) - Bavarian Nordic A/S :REG-BAVARIAN NORDIC LAUNCHES SHARE BUY-BACK PROGRAM TO HEDGE INCENTIVE SCHEME OBLIGATIONS.COMPANY INTENDS TO BUY BACK 12,156 OF ITS OWN SHARES..  Full Article

Bavarian Nordic names Christopher Heery Chief Medical Officer
Wednesday, 28 Sep 2016 

Bavarian Nordic A/S : Appoints Christopher Heery, M.D., as Chief Medical Officer .Most recently, Dr. Heery was Director of Clinical Trials Group of Laboratory of Tumor Immunology and Biology at National Cancer Institute.  Full Article

Bavarian Nordic Q2 EBIT swings to loss DKK 54.0 million
Wednesday, 17 Aug 2016 

Bavarian Nordic A/S : H1 revenue 139 million Danish crowns ($21 million) versus 624 million crowns year ago . Q2 revenue 116.6 million crowns versus 389.1 million crowns year ago . Q2 EBIT loss 54.0 million crowns versus profit 125.0 million crowns year ago .Maintains its financial expectations for 2016.  Full Article

Bavarian Nordic: Expansion of IMVAMUNE orders from Canada
Wednesday, 15 Jun 2016 

Bavarian Nordic A/S : Announces expansion of IMVAMUNE orders from Canadian government . Canadian government exercised option for supply of 171,000 doses of IMVAMUNE smallpox vaccine to national stockpile at total value of $7.7 million .Says contents of this announcement do not affect company's expectations for financial results for 2016.  Full Article

Bavarian Nordic Q1 EBIT loss increases to DKK 153 million
Friday, 13 May 2016 

Bavarian Nordic A/S : Q1 revenue 23 million Danish crowns ($3.52 million) versus 235 million crowns year ago . Q1 EBIT loss 153 million crowns versus loss 40 million crowns year ago .Maintains its financial expectations for 2016.  Full Article

Bavarian Nordic A/S: Positive data for Ebola vaccine regimen
Monday, 18 Apr 2016 

Bavarian Nordic A/S:Results of Phase 1 study of a preventive Ebola vaccine regimen suggest that regimen was well-tolerated by healthy volunteers and did not result in any vaccine-related serious adverse events.Study tested vaccine regimen containing two components, of which one was based on MVA-BN technology from Bavarian Nordic.Confirmed data from a Phase 1 study of a preventive Ebola vaccine regimen have been published in The Journal of the American Medical Association.  Full Article

Bavarian Nordic completes a private placement at market price
Monday, 18 Apr 2016 

Bavarian Nordic A/S:Completes a private placement at market price.Says subscription price is 240 Danish crowns per share.Raises gross proceeds in private placement of about 665 million crowns.Raises expectations to FY 2016 year-end cash preparedness to level of 1.90 billion crowns from 1.30 billion crowns.  Full Article

BRIEF-‍Bavarian Nordic says BARDA exercised option under the contract for freeze-dried Imvamune

* ‍BAVARIAN NORDIC ANNOUNCES EXERCISE OF CLINICAL OPTION BY US GOVERNMENT UNDER CONTRACT FOR FREEZE-DRIED IMVAMUNE SMALLPOX VACCINE​